Boston Heart Diagnostics rounds out offerings, launches FDA-cleared MPO
In a bid to round out its commercial offerings for detecting heart attack and stroke, Boston Heart Diagnostics (Framingham, Massachusetts) reported the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.
2013 was the 'best of times', 'worst of times' for med-tech
In reviewing Medical Device Daily's top stories and industry trends that emerged over the past year, the familiar words of Charles Dickens seems to be an appropriate way to describe the state of the industry in 2013: It was the best of times, it was the worst of times. The medical device sector underwent immense change in 2013, and while it may be easier to think of the negative headlines that impacted the industry over the past 12 months, there were a number of positive trends that emerged last year. For better or for worse, 2013 was a transformative year for medical technology worldwide.
mHealth opportunities in Latin America on the rise
With mobile phones and tablets penetrating deeper into Latin America every year, the opportunities for mHealth developers are growing rapidly.